Our previous study also illustrated that high percentages of IFN-γ-producing naïve CD4+ T cells and PD-1+CD4+ memory T cells were associated with better response to anti-PD-1 treatment in NSCLC patients (11). This evidence concerns the gene CD4 and non-small cell lung carcinoma.